UY27316A1 - Derivados ácidos de azol sustituidos, útiles como agentes antidiabéticos y antiobesidad y método - Google Patents
Derivados ácidos de azol sustituidos, útiles como agentes antidiabéticos y antiobesidad y métodoInfo
- Publication number
- UY27316A1 UY27316A1 UY27316A UY27316A UY27316A1 UY 27316 A1 UY27316 A1 UY 27316A1 UY 27316 A UY27316 A UY 27316A UY 27316 A UY27316 A UY 27316A UY 27316 A1 UY27316 A1 UY 27316A1
- Authority
- UY
- Uruguay
- Prior art keywords
- antidiabétic
- antiobesity
- agents
- useful
- acid derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Reproductive Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
Se proporcionan compuestos que tienen la estructura I. La presente invención proporciona además un método para el tratamiento de la obesidad y la disciplina de mamíferos, incluyendo a los humanos, a través de la inhibición simultánea del receptor-y activado proliferados de la peroxisona (PARy) y la estimulación del receptor-a (PPARy) activado proliferador de la peroxisona.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29438001P | 2001-05-30 | 2001-05-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY27316A1 true UY27316A1 (es) | 2002-12-31 |
Family
ID=23133159
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY27316A UY27316A1 (es) | 2001-05-30 | 2002-05-30 | Derivados ácidos de azol sustituidos, útiles como agentes antidiabéticos y antiobesidad y método |
Country Status (17)
Country | Link |
---|---|
US (1) | US20030092736A1 (es) |
EP (1) | EP1390363A4 (es) |
JP (1) | JP2004536070A (es) |
AU (1) | AU2002259306B2 (es) |
CA (1) | CA2449160A1 (es) |
CZ (1) | CZ20033230A3 (es) |
DE (1) | DE02729306T1 (es) |
ES (1) | ES2214168T1 (es) |
HU (1) | HUP0401504A3 (es) |
MX (1) | MXPA03010997A (es) |
NO (1) | NO327089B1 (es) |
PE (1) | PE20030043A1 (es) |
PL (1) | PL367066A1 (es) |
TR (1) | TR200400650T3 (es) |
TW (1) | TWI235061B (es) |
UY (1) | UY27316A1 (es) |
WO (1) | WO2002096358A2 (es) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003256419A1 (en) * | 2002-08-21 | 2004-03-11 | Merck & Co., Inc. | Combination therapy using a dual ppar alpha/gamma agonist and an angiotensin ii type i receptor antagonist |
EP1424070A1 (en) * | 2002-11-28 | 2004-06-02 | Fournier Laboratories Ireland Limited | Combination of a PPAR alpha agonist and metformin for decreasing the serum triglycerides |
SE0300988D0 (sv) * | 2003-04-03 | 2003-04-03 | Astrazeneca Ab | New use |
WO2004108126A1 (en) * | 2003-06-06 | 2004-12-16 | Snowden Pharmaceuticals, Llc | Fibric acid derivatives for the treatment of irritable bowel syndrome |
AU2004255342C1 (en) * | 2003-07-08 | 2009-05-14 | Novartis Ag | Benzenesulfonylamino compounds and pharmaceutical compositions containing these compounds |
ES2390053T3 (es) * | 2003-09-22 | 2012-11-06 | Ono Pharmaceutical Co., Ltd. | Derivado de ácido fenilacético, procedimiento para producir el mismo y uso |
EP1734953A4 (en) * | 2004-03-02 | 2008-08-20 | Abeille Pharmaceuticals Inc | CO-PR PARATIONS OF KITS OF BIOACTIVE AGENTS |
EP1750862B1 (en) | 2004-06-04 | 2011-01-05 | Teva Pharmaceutical Industries Ltd. | Pharmaceutical composition containing irbesartan |
CN1304393C (zh) * | 2004-07-01 | 2007-03-14 | 中国药科大学 | 取代的吡唑啉酮衍生物及其制备方法与药用组合物 |
KR100706600B1 (ko) * | 2004-11-25 | 2007-04-12 | 주식회사 엘지생명과학 | PPAR gamma와 PPAR alpha의 활성을항진시키는 신규 화합물, 그것의 제조방법, 및 그것을함유한 약제 조성물 |
WO2006057503A1 (en) * | 2004-11-25 | 2006-06-01 | Lg Life Sciences, Ltd. | NOVEL COMPOUNDS AS AGONIST FOR PPARϜ AND PPARα, METHOD FOR PREPARATION OF THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME |
WO2007058504A1 (en) * | 2005-11-21 | 2007-05-24 | Lg Life Sciences, Ltd. | Novel compounds as agonist for ppar gamma and ppar alpha, method for preparation of the same, and pharmaceutical composition containing the same |
WO2008127813A1 (en) * | 2007-03-09 | 2008-10-23 | Hiberna Corporation | Hibernation-related genes and proteins, activators and inhibitors thereof and methods of use |
US8252789B2 (en) | 2007-11-29 | 2012-08-28 | Neuraltus Pharmaceuticals, Inc. | Compositions and methods for treating lysosomal disorders |
MX2011004535A (es) * | 2008-10-29 | 2011-11-18 | Deciphera Pharmaceuticals Llc | Ciclopropanamidas y analogos que exhiben actividades anti-cancer y anti-proliferativas. |
WO2020113094A1 (en) | 2018-11-30 | 2020-06-04 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
CN109498622A (zh) * | 2018-12-28 | 2019-03-22 | 成都恒瑞制药有限公司 | 一种氯沙坦钾与罗格列酮组合物及其制备方法 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1003445B (zh) * | 1984-10-03 | 1989-03-01 | 武田药品工业株式会社 | 噻唑烷二酮衍生物,其制备方法和用途 |
US5591862A (en) * | 1993-06-11 | 1997-01-07 | Takeda Chemical Industries, Ltd. | Tetrazole derivatives, their production and use |
SK15522001A3 (sk) * | 1999-04-28 | 2002-06-04 | Aventis Pharma Deutschland Gmbh | Deriváty kyselín s tromi arylovými zvyškami ako ligandy receptorov PPAR a farmaceutické kompozície, ktoré ich obsahujú |
WO2001017994A1 (en) * | 1999-09-08 | 2001-03-15 | Glaxo Group Limited | Oxazole ppar antagonists |
PL356487A1 (en) * | 1999-11-10 | 2004-06-28 | Takeda Chemical Industries, Ltd. | 5-membered n-heterocyclic compounds with hypoglycemic and hypolipidemic activity |
EP1394154A4 (en) * | 2001-03-23 | 2005-05-18 | Takeda Pharmaceutical | HETEROCYCLIC DERIVATIVE WITH FIVE MEMBERS OF ALKANOIC ACID |
-
2002
- 2002-05-22 US US10/153,454 patent/US20030092736A1/en not_active Abandoned
- 2002-05-23 CZ CZ20033230A patent/CZ20033230A3/cs unknown
- 2002-05-23 MX MXPA03010997A patent/MXPA03010997A/es active IP Right Grant
- 2002-05-23 DE DE0001390363T patent/DE02729306T1/de active Pending
- 2002-05-23 PL PL02367066A patent/PL367066A1/xx not_active Application Discontinuation
- 2002-05-23 EP EP02729306A patent/EP1390363A4/en not_active Withdrawn
- 2002-05-23 CA CA002449160A patent/CA2449160A1/en not_active Abandoned
- 2002-05-23 JP JP2002592871A patent/JP2004536070A/ja active Pending
- 2002-05-23 TR TR2004/00650T patent/TR200400650T3/xx unknown
- 2002-05-23 AU AU2002259306A patent/AU2002259306B2/en not_active Ceased
- 2002-05-23 ES ES02729306T patent/ES2214168T1/es active Pending
- 2002-05-23 WO PCT/US2002/016633 patent/WO2002096358A2/en active Application Filing
- 2002-05-23 HU HU0401504A patent/HUP0401504A3/hu unknown
- 2002-05-24 TW TW091111100A patent/TWI235061B/zh not_active IP Right Cessation
- 2002-05-30 UY UY27316A patent/UY27316A1/es not_active Application Discontinuation
- 2002-05-30 PE PE2002000455A patent/PE20030043A1/es not_active Application Discontinuation
-
2003
- 2003-11-28 NO NO20035312A patent/NO327089B1/no not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
CZ20033230A3 (cs) | 2004-02-18 |
MXPA03010997A (es) | 2004-02-27 |
AU2002259306B2 (en) | 2007-02-08 |
TR200400650T3 (tr) | 2004-06-21 |
EP1390363A2 (en) | 2004-02-25 |
WO2002096358A2 (en) | 2002-12-05 |
WO2002096358A3 (en) | 2003-03-27 |
HUP0401504A2 (hu) | 2004-11-29 |
EP1390363A4 (en) | 2011-01-05 |
ES2214168T1 (es) | 2004-09-16 |
JP2004536070A (ja) | 2004-12-02 |
US20030092736A1 (en) | 2003-05-15 |
CA2449160A1 (en) | 2002-12-05 |
PE20030043A1 (es) | 2003-02-05 |
DE02729306T1 (de) | 2004-08-26 |
PL367066A1 (en) | 2005-02-21 |
TWI235061B (en) | 2005-07-01 |
NO327089B1 (no) | 2009-04-20 |
NO20035312D0 (no) | 2003-11-28 |
HUP0401504A3 (en) | 2008-05-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY27316A1 (es) | Derivados ácidos de azol sustituidos, útiles como agentes antidiabéticos y antiobesidad y método | |
UY28757A1 (es) | Compuestos de pirazolina substituidos, su preparación y su uso como medicamentos | |
CR7877A (es) | Derivados de 4-tetrazolil-4-fenilpiperidina para tratar el dolor | |
GT200500325A (es) | Pirazolo-pirimidinas 1,4-sustituidas como inhibidores de quinasa | |
UY31068A1 (es) | Ligandos purinoreceptores p2x, metodos para la prparacion de los mismos, composiciones farmaceuticas que los contienen y sus usos 570 | |
UY26130A1 (es) | Compuestos para tratar la obesidad | |
ECSP20046463A (es) | Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas | |
PA8680701A1 (es) | Derivados de oxindol | |
DOP2009000165A (es) | Derivados de oxindol sustituido, medicamentos que los comprenden y uso de los mismos | |
SV2004001691A (es) | Nuevos derivados de fluoroglicosidos aromaticos, medicamentos que contienen compuestos y sus usos | |
SV2004001690A (es) | Nuevos derivados de fluoroglicosidos heterociclicos, medicamentos que contienen estos compuestos, y el uso de los mismos | |
HN2003000207A (es) | Moduladores del receptor de glucocorticoides | |
ECSP045474A (es) | 1-(aminoalquil)-3-sulfonilazaindoles como ligandos de 5-hidroxitriptamina-6 | |
AR057868A1 (es) | Metodos en los que se usa 3-(4-amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidin-2,6-diona para el tratamiento de ciertas leucemias | |
ECSP088984A (es) | Derivados de triazol ii | |
AR112101A1 (es) | Tinostamustina para usar en el tratamiento de la leucemia prolinfocítica de celulas t (t-pll). | |
HN2003000063A (es) | Derivados de nicotinamida y una sal de tiotropio en combinacion para el tratamiento de enfermedades. | |
CL2019000768A1 (es) | Compuestos de aza-indazol para usar en lesiones de tendones y/o ligamentos. | |
CO2022015630A2 (es) | Pirrolopirimidinaminas como inhibidores del sistema del complemento | |
CR20220199A (es) | Inhibidores del factor d del complemento para administración oral | |
BR0107628A (pt) | l,2-diarilbenzimidazóis para tratamento de doenças que estão associadas a uma ativação microglial | |
UY28925A1 (es) | Nuevos derivados de aminopiridina y su uso como fármacos | |
AR128500A1 (es) | Inhibidores de arn helicasa dhx9 y usos de los mismos | |
CL2023001339A1 (es) | Un inhibidor de magl. | |
PA8597501A1 (es) | Derivados azabiciclicos de piridiloximetilo y bencisoxazol |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20150126 |